Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 7.08 USD 4.12% Market Closed
Market Cap: 491.1m USD

Relative Value

The Relative Value of one BCYC stock under the Base Case scenario is 7.76 USD. Compared to the current market price of 7.08 USD, Bicycle Therapeutics PLC is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BCYC Relative Value
Base Case
7.76 USD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
33
Median 3Y
30.2
Median 5Y
41.1
Industry
7.9
Forward
14.9
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-6.9
Industry
23.7
Forward
-1.8
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-12.2
Industry
22
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-10.7
Industry
24.3
vs History
88
vs Industry
64
Median 3Y
1.9
Median 5Y
2.6
Industry
3.3
vs History
vs Industry
24
Median 3Y
14
Median 5Y
20.9
Industry
8.2
Forward
-4.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
12
vs Industry
17
Median 3Y
-2.9
Median 5Y
-3.5
Industry
6.1
Forward
0.5
vs History
12
vs Industry
16
Median 3Y
-2.7
Median 5Y
-3.4
Industry
6.5
Forward
0.5
vs History
12
vs Industry
18
Median 3Y
-3.4
Median 5Y
-6.6
Industry
7.9
vs History
12
vs Industry
14
Median 3Y
-3.3
Median 5Y
-5.5
Industry
6.3
vs History
vs Industry
18
Median 3Y
4.3
Median 5Y
6.6
Industry
5.7

Multiples Across Competitors

BCYC Competitors Multiples
Bicycle Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
490.7m USD 17.3 -2 0.6 0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 790 068.7 -160 599.2 -195 018.6 -192 793.3
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.9 -532 -579.3 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD 16.5 1 216.4 164 198.9
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.5 57.8 59.4
P/E Multiple
Earnings Growth PEG
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average P/E: 191.7
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 599.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 216.4
N/A N/A
NL
argenx SE
XBRU:ARGX
33.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average EV/EBITDA: 35.8
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 018.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164
N/A N/A
NL
argenx SE
XBRU:ARGX
57.8
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Bicycle Therapeutics PLC
NASDAQ:BCYC
Average EV/EBIT: 41.3
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59.4
N/A N/A